Importance

Loading Importance Indicators...

Abstract

Compounds are described of the general formula: ##STR1## wherein: R.sub.1 is acyl of the formula --C(=O)-R.sub.5 : R.sub.2, R.sub.3, R.sub.4, R.sub.6, R.sub.7 and R.sub.8 are each selected from the group consisting of hydrogen and acyl of the formula: --C(=O)-R.sub.5 wherein R.sub.5 is selected from the group consisting of alkyls, substituted alkyls, alkenyls, substituted alkenyls, cycloalkyls, substituted cycloalkyls, arylalkylenes, substituted arylalkylenes, alkylenecycloalkyls, alkylene substituted cycloalkyls, alkynyls, substituted alkynyls, aryls and substituted aryls, wherein R.sub.2, R.sub.3 and R.sub.4 are selected such that at least one of R.sub.2, R.sub.3 and R.sub.4 is an acyl. When R.sub.2, R.sub.3 and R.sub.4 include one or more acyls that are not identical to the acyl of R.sub.1, these compounds of formula I are novel compounds. The invention also includes processes to produce the compounds of formula I. Compounds of formula I complex and/or chelate tissue tri-valent ions, especially iron and aluminum (Fe.sup.+++, Al.sup.+++), when administered to a human being, and are therefore useful in therapy in the treatment of diseases in which tissue ion levels in the body have increased or toxic levels. These iron-related diseases include, for example, thalassemia major, sideroachrestic anemic, BlacKfan-Diamond anemia, aplastic anemia, sickle cell anemia, hemolytic anemias and hemosiderosis brought about by multiple blood transfusions including treatment for the anemia accompanying conditions requiring kidney dialysis. Aluminum-related diseases or conditions include Alzheimer's disease, senile dementia and dialysis encephalopathy.

Loading the Abstract Image...

First Claim